
|Videos|October 18, 2016
How Myriad's myPlan Addresses the Risk of Recurrence in Lung Cancer
Author(s)Benjamin P. Levy, MD
Benjamin P. Levy, MD, discusses how Myriad's myPlan addresses the risk of recurrence in lung cancer.
Advertisement
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves T-DXd Plus Pertuzumab for HER2-Positive Breast Cancer
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Roxadustat Granted Orphan Drug Designation for Myelodysplastic Syndromes
4
Breast Cancer Test Using Proteomic Profiling and AI Demonstrates High Performance
5










































